S.-W. Kim

Belotecan, new camptothecin analogue, is active in patients with small-cell lung cancer: results of a multicenter early phase II study

D.H. Lee, S.-W. Kim, Cheolwon Suh et al. · Annals of Oncology · 2007 · 58 citations · Full text

Medicine, Pharmacology, Pathology +9

Nivolumab (NIVO) + low-dose ipilimumab (IPI) vs platinum-doublet chemotherapy (chemo) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): CheckMate 227 part 1 final analysis

Solange Peters, S.S. Ramalingam, Luis Paz‐Ares et al. · Annals of Oncology · 2019 · 32 citations · Full text

Part 1, Oncology, Low-dose Ipilimumab +7

First-line nivolumab + ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients

Kenneth J. O’Byrne, K.H. Lee, S.-W. Kim et al. · ESMO Open · 2022 · 21 citations · Full text

Primary results of ALESIA: A randomised, phase III, open-label study of alectinib vs crizotinib in Asian patients with treatment-naïve ALK+ advanced NSCLC

C. Zhou, You Lü, S.-W. Kim et al. · Annals of Oncology · 2018 · 12 citations

Oncology, Primary Results, Phase Iii +4